RVMD
$194.19-1.20%
as of close, Oct 21, 2026
☾ AH $194.19 -1.20%
Revolution Medicines Inc.Stock · HealthcareNasdaq Composite · 0.07% of ONEQUS Stock Market · 0.05% of VTIRussell 1000 · 0.05% of IWBRussell 3000 · 0.05% of IWVMSCI ACWI · 0.03% of ACWIMSCI World · 0.03% of URTH
RVMD SEC filings (2026)
CIK 1628171 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
858 filings on EDGAR since 2016 · 7 annual, 20 quarterly, 72 current · financial statements · earnings
Latest 10-K
Feb 25, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 5, 2026
quarter to Jun 30, 2026
Latest 8-K
Oct 13, 2026
New financial obligation; Other events
Last earnings release
Aug 5, 2026
−$2.34 vs −$1.93 · ▲ 0.3%
Filings on file
858
since 2016, 585 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 138-K8-K · New financial obligation; Other events
September 2026
- Sep 29Insider saleSandler Alan B. (Chief Development Officer) sold 6,309 shares for $1.3M at $200.82–$204.72 under a 10b5-1 plan
- Sep 25Insider saleMancini Anthony (See Remarks) sold 3,121 shares for $626K at $200.54 under a 10b5-1 plan
- Sep 25Insider saleCislini Jeff (SVP & General Counsel) sold 765 shares for $159K at $207.32 under a 10b5-1 plan
- Sep 24Insider saleMancini Anthony (See Remarks) sold 587 shares for $117K at $200.00 under a 10b5-1 plan
- Sep 22Insider saleANDERSON ELIZABETH M (Director) sold 10,143 shares for $2.0M at $191.85–$195.15 under a 10b5-1 plan
- Sep 18Insider saleMancini Anthony (See Remarks) sold 1,764 shares for $347K at $196.94 under a 10b5-1 plan
- Sep 16Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 13,988 shares for $2.8M at $195.01–$199.30 under a 10b5-1 plan
- Sep 16Insider saleKelsey Stephen Michael (See Remarks) sold 5,569 shares for $1.1M at $195.01–$199.30 under a 10b5-1 plan
- Sep 16Insider saleHorn Margaret A (Chief Operating Officer) sold 4,967 shares for $990K at $195.01–$199.30 under a 10b5-1 plan
- Sep 16Insider saleAnders Jack (Chief Financial Officer) sold 4,053 shares for $808K at $195.00–$199.30 under a 10b5-1 plan
- Sep 16Insider saleCislini Jeff (SVP & General Counsel) sold 3,366 shares for $671K at $195.01–$199.30 under a 10b5-1 plan
- Sep 16Insider saleMancini Anthony (See Remarks) sold 1,774 shares for $353K at $195.05–$199.30 under a 10b5-1 plan
- Sep 16Insider saleSandler Alan B. (Chief Development Officer) sold 341 shares for $68K at $194.96–$199.30 under a 10b5-1 plan
- Sep 11Insider saleKelsey Stephen Michael (See Remarks) sold 92,531 shares for $18.7M at $198.55–$205.81 under a 10b5-1 plan
- Sep 10Insider saleMancini Anthony (See Remarks) sold 15,448 shares for $3.2M at $203.28–$207.17 under a 10b5-1 plan
- Sep 8Insider saleKim Lorence H. (Director) sold 17,090 shares for $3.6M at $206.60–$212.27 under a 10b5-1 plan
- Sep 18-K8-K · Material definitive agreement; New financial obligation
August 2026
- Aug 31Insider saleKim Lorence H. (Director) sold 56,000 shares for $11.4M at $200.56–$206.15 under a 10b5-1 plan
- Aug 268-K8-K · Other events
- Aug 21Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 86,000 shares for $18.0M at $207.23–$212.08 under a 10b5-1 plan
- Aug 21Insider saleCislini Jeff (General Counsel) sold 56,894 shares for $11.9M at $207.24–$212.06 under a 10b5-1 plan
- Aug 5EarningsEarnings release — EPS −$2.34 vs −$1.93 est. (−21.2%) 0.3%
- Aug 5ReportQuarterly report, Q2 2026 — net income −$644.4M, EPS −$3.06
June 2026
- Jun 29Insider salePatel Sushil (Director) sold 5,580 shares for $1.0M at $183.17–$192.61 under a 10b5-1 plan
- Jun 24Insider saleAnders Jack (Chief Financial Officer) sold 20,000 shares for $3.4M at $167.35–$170.32 under a 10b5-1 plan
- Jun 228-K8-K · Directors or officers; compensation; Shareholder vote results
- Jun 17Insider saleHorn Margaret A (Chief Operating Officer) sold 29,600 shares for $4.7M at $160.12 under a 10b5-1 plan
- Jun 16Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 10,020 shares for $1.6M at $156.12 under a 10b5-1 plan
- Jun 16Insider saleMancini Anthony (See Remarks) sold 4,615 shares for $720K at $156.12
- Jun 16Insider saleKelsey Stephen Michael (See Remarks) sold 4,175 shares for $652K at $156.12 under a 10b5-1 plan
- Jun 16Insider saleAnders Jack (Chief Financial Officer) sold 2,722 shares for $425K at $156.12 under a 10b5-1 plan
- Jun 16Insider saleCislini Jeff (General Counsel) sold 2,157 shares for $337K at $156.12 under a 10b5-1 plan
- Jun 15Insider saleHorn Margaret A (Chief Operating Officer) sold 60,400 shares for $9.7M at $160.17 under a 10b5-1 plan
- Jun 11Insider saleHorn Margaret A (Chief Operating Officer) sold 10,000 shares for $1.5M at $144.28–$150.17 under a 10b5-1 plan
May 2026
April 2026
- Apr 28ProxyProxy · Additional proxy materials
- Apr 28ProxyProxy · Annual report to shareholders
- Apr 27Insider saleMancini Anthony (See Remarks) sold 3,120 shares for $413K at $131.66–$134.34 under a 10b5-1 plan
- Apr 27ProxyProxy · Proxy statement
- Apr 178-K8-K · Material definitive agreement; New financial obligation; Other events
- Apr 168-K8-K · Other events
- Apr 15Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 120,000 shares for $18.0M at $150.09 under a 10b5-1 plan
- Apr 138-K8-K · Other events
March 2026
- Mar 25Insider saleMancini Anthony (See Remarks) sold 37,450 shares for $3.6M at $93.22–$97.21 under a 10b5-1 plan
- Mar 19Insider saleCislini Jeff (General Counsel) sold 1,163 shares for $113K at $97.44 under a 10b5-1 plan
- Mar 17Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 12,871 shares for $1.3M at $99.48 under a 10b5-1 plan
- Mar 17Insider saleHorn Margaret A (Chief Operating Officer) sold 4,583 shares for $456K at $99.48 under a 10b5-1 plan
- Mar 17Insider saleKelsey Stephen Michael (See Remarks) sold 4,302 shares for $428K at $99.48 under a 10b5-1 plan
- Mar 17Insider saleAnders Jack (Chief Financial Officer) sold 2,753 shares for $274K at $99.48 under a 10b5-1 plan
- Mar 17Insider saleWei Lin (Chief Medical Officer) sold 2,073 shares for $206K at $99.48 under a 10b5-1 plan
- Mar 17Insider saleWang Xiaolin (See Remarks) sold 2,010 shares for $200K at $99.48 under a 10b5-1 plan
- Mar 17Insider saleCislini Jeff (General Counsel) sold 1,795 shares for $179K at $99.48 under a 10b5-1 plan
- Mar 2Insider saleGOLDSMITH MARK A (See Remarks · Director) sold 36,000 shares for $3.6M at $98.17–$102.20 under a 10b5-1 plan
February 2026
January 2026
- Jan 21Insider saleCislini Jeff (General Counsel) sold 908 shares for $105K at $115.60 under a 10b5-1 plan
- Jan 7Insider saleHorn Margaret A (Chief Operating Officer) sold 75,000 shares for $7.5M at $100.02–$102.90 under a 10b5-1 plan
- Jan 7Insider saleAnders Jack (Chief Financial Officer) sold 10,000 shares for $980K at $98.00 under a 10b5-1 plan
November 2025
- Nov 5EarningsEarnings release — EPS −$1.61 vs −$1.39 est. (−15.8%) 3.4%
- Nov 5ReportQuarterly report, Q3 2025 — net income −$305.2M, EPS −$1.61
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $140.5M in 46 sales and bought nothing on the open market; 69 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 29, 2026Form 4 | Sandler Alan B.Chief Development OfficerSold · $1.3M · 6,309 sh · 10b5-1 |
| Sep 25, 2026Form 4 | Mancini AnthonySee RemarksSold · $626K · 3,121 sh · 10b5-1 |
| Sep 25, 2026Form 4 | Cislini JeffSVP & General CounselSold · $159K · 765 sh · 10b5-1 |
| Sep 24, 2026Form 4 | Mancini AnthonySee RemarksSold · $117K · 587 sh · 10b5-1 |
| Sep 22, 2026Form 4 | ANDERSON ELIZABETH MDirectorSold · $2.0M · 10,143 sh · 10b5-1 |
| Sep 18, 2026Form 4 | Mancini AnthonySee RemarksSold · $347K · 1,764 sh · 10b5-1 |
| Sep 16, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $2.8M · 13,988 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Kelsey Stephen MichaelSee RemarksSold · $1.1M · 5,569 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $990K · 4,967 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Anders JackChief Financial OfficerSold · $808K · 4,053 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Cislini JeffSVP & General CounselSold · $671K · 3,366 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Mancini AnthonySee RemarksSold · $353K · 1,774 sh · 10b5-1 |
| Sep 16, 2026Form 4 | Sandler Alan B.Chief Development OfficerSold · $68K · 341 sh · 10b5-1 |
| Sep 11, 2026Form 4 | Kelsey Stephen MichaelSee RemarksSold · $18.7M · 92,531 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mancini AnthonySee RemarksSold · $3.2M · 15,448 sh · 10b5-1 |
| Sep 8, 2026Form 4 | Kim Lorence H.DirectorSold · $3.6M · 17,090 sh · 10b5-1 |
| Aug 31, 2026Form 4 | Kim Lorence H.DirectorSold · $11.4M · 56,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $18.0M · 86,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | Cislini JeffGeneral CounselSold · $11.9M · 56,894 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Patel SushilDirectorSold · $1.0M · 5,580 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Anders JackChief Financial OfficerSold · $3.4M · 20,000 sh · 10b5-1 |
| Jun 17, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $4.7M · 29,600 sh · 10b5-1 |
| Jun 16, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $1.6M · 10,020 sh · 10b5-1 |
| Jun 16, 2026Form 4 | Mancini AnthonySee RemarksSold · $720K · 4,615 sh |
| Jun 16, 2026Form 4 | Kelsey Stephen MichaelSee RemarksSold · $652K · 4,175 sh · 10b5-1 |
| Jun 16, 2026Form 4 | Anders JackChief Financial OfficerSold · $425K · 2,722 sh · 10b5-1 |
| Jun 16, 2026Form 4 | Cislini JeffGeneral CounselSold · $337K · 2,157 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $9.7M · 60,400 sh · 10b5-1 |
| Jun 11, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $1.5M · 10,000 sh · 10b5-1 |
| May 26, 2026Form 4 | Mancini AnthonySee RemarksSold · $481K · 3,121 sh · 10b5-1 |
| Apr 27, 2026Form 4 | Mancini AnthonySee RemarksSold · $413K · 3,120 sh · 10b5-1 |
| Apr 15, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $18.0M · 120,000 sh · 10b5-1 |
| Mar 25, 2026Form 4 | Mancini AnthonySee RemarksSold · $3.6M · 37,450 sh · 10b5-1 |
| Mar 19, 2026Form 4 | Cislini JeffGeneral CounselSold · $113K · 1,163 sh · 10b5-1 |
| Mar 17, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $1.3M · 12,871 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $456K · 4,583 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Kelsey Stephen MichaelSee RemarksSold · $428K · 4,302 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Anders JackChief Financial OfficerSold · $274K · 2,753 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Wei LinChief Medical OfficerSold · $206K · 2,073 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Wang XiaolinSee RemarksSold · $200K · 2,010 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Cislini JeffGeneral CounselSold · $179K · 1,795 sh · 10b5-1 |
| Mar 2, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorSold · $3.6M · 36,000 sh · 10b5-1 |
| Jan 21, 2026Form 4 | Cislini JeffGeneral CounselSold · $105K · 908 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Horn Margaret AChief Operating OfficerSold · $7.5M · 75,000 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Anders JackChief Financial OfficerSold · $980K · 10,000 sh · 10b5-1 |
| Jun 16, 2025Form 4 | Horn Margaret AChief Operating OfficerSold · $558K · 3,575 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 69 transactions
| Date | Insider |
|---|---|
| Sep 29, 2026Form 4 | Sandler Alan B.Chief Development OfficerExercise or conversion · $353K · 6,000 sh · 10b5-1 |
| Sep 29, 2026Form 4 | Sandler Alan B.Chief Development OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 6,000 sh · 10b5-1 |
| Sep 25, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · $105K · 3,121 sh · 10b5-1 |
| Sep 25, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · Stock Option (Right to Buy) · $0 · 3,121 sh · 10b5-1 |
| Sep 22, 2026Form 4 | ANDERSON ELIZABETH MDirectorExercise or conversion · $5,678 · 5,070 sh · 10b5-1 |
| Sep 22, 2026Form 4 | ANDERSON ELIZABETH MDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 5,070 sh · 10b5-1 |
| Sep 11, 2026Form 4 | Kelsey Stephen MichaelSee RemarksExercise or conversion · $3.9M · 92,531 sh · 10b5-1 |
| Sep 11, 2026Form 4 | Kelsey Stephen MichaelSee RemarksExercise or conversion · Stock Option (Right to Buy) · $3.9M · 92,531 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · $315K · 9,363 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · Stock Option (Right to Buy) · $0 · 9,363 sh · 10b5-1 |
| Aug 21, 2026Form 4 | Cislini JeffGeneral CounselExercise or conversion · $1.1M · 56,280 sh · 10b5-1 |
| Aug 21, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · $378K · 80,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 80,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | Cislini JeffGeneral CounselExercise or conversion · Stock Option (Right to Buy) · $0 · 56,280 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Patel SushilDirectorExercise or conversion · $111K · 2,955 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Patel SushilDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 2,955 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Anders JackChief Financial OfficerExercise or conversion · $371K · 20,000 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Anders JackChief Financial OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 20,000 sh · 10b5-1 |
| Jun 18, 2026Form 4 | Borellini FlaviaDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Patel SushilDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Clyburn FrankDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Horning SandraDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | ANDERSON ELIZABETH MDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Borisy AlexisDirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Kim Lorence H.DirectorAward · Stock Option (Right to Buy) · $0 · 3,127 sh |
| Jun 18, 2026Form 4 | Borellini FlaviaDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | Patel SushilDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | Clyburn FrankDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | Horning SandraDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | ANDERSON ELIZABETH MDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | Borisy AlexisDirectorAward · $0 · 1,191 sh |
| Jun 18, 2026Form 4 | Kim Lorence H.DirectorAward · $0 · 1,191 sh |
| Jun 17, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · $803K · 29,600 sh · 10b5-1 |
| Jun 17, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 29,600 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · $2.0M · 60,400 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 60,400 sh · 10b5-1 |
| Jun 11, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · $409K · 10,000 sh · 10b5-1 |
| Jun 11, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1 |
| May 26, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · $105K · 3,121 sh · 10b5-1 |
| May 26, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · Stock Option (Right to Buy) · $0 · 3,121 sh · 10b5-1 |
| Apr 27, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · $105K · 3,120 sh · 10b5-1 |
| Apr 27, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · Stock Option (Right to Buy) · $0 · 3,120 sh · 10b5-1 |
| Apr 15, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · $553K · 120,000 sh · 10b5-1 |
| Apr 15, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 120,000 sh · 10b5-1 |
| Mar 25, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · $1.3M · 37,450 sh · 10b5-1 |
| Mar 25, 2026Form 4 | Mancini AnthonySee RemarksExercise or conversion · Stock Option (Right to Buy) · $0 · 37,450 sh · 10b5-1 |
| Mar 4, 2026Form 4 | ANDERSON ELIZABETH MDirectorGift · $0 · 30,000 sh |
| Mar 2, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · $123K · 30,000 sh · 10b5-1 |
| Mar 2, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 30,000 sh · 10b5-1 |
| Mar 1, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorAward · Stock Option (Right to Buy) · $0 · 128,600 sh · 10b5-1 |
| Mar 1, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorAward · $0 · 57,100 sh · 10b5-1 |
| Mar 1, 2026Form 4 | Horn Margaret AChief Operating OfficerAward · Stock Option (Right to Buy) · $0 · 47,600 sh |
| Mar 1, 2026Form 4 | Kelsey Stephen MichaelSee RemarksAward · Stock Option (Right to Buy) · $0 · 47,600 sh |
| Mar 1, 2026Form 4 | Anders JackChief Financial OfficerAward · Stock Option (Right to Buy) · $0 · 45,400 sh |
| Mar 1, 2026Form 4 | Wei LinChief Medical OfficerAward · Stock Option (Right to Buy) · $0 · 34,000 sh |
| Mar 1, 2026Form 4 | Wang XiaolinSee RemarksAward · Stock Option (Right to Buy) · $0 · 34,000 sh |
| Mar 1, 2026Form 4 | Cislini JeffGeneral CounselAward · Stock Option (Right to Buy) · $0 · 32,500 sh |
| Mar 1, 2026Form 4 | Horn Margaret AChief Operating OfficerAward · $0 · 21,100 sh |
| Mar 1, 2026Form 4 | Kelsey Stephen MichaelSee RemarksAward · $0 · 21,100 sh |
| Mar 1, 2026Form 4 | Anders JackChief Financial OfficerAward · $0 · 20,200 sh |
| Mar 1, 2026Form 4 | Wei LinChief Medical OfficerAward · $0 · 15,100 sh |
| Mar 1, 2026Form 4 | Wang XiaolinSee RemarksAward · $0 · 15,100 sh |
| Mar 1, 2026Form 4 | Cislini JeffGeneral CounselAward · $0 · 14,500 sh |
| Feb 6, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · $13K · 24,010 sh |
| Feb 6, 2026Form 4 | GOLDSMITH MARK ASee Remarks · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 24,010 sh |
| Jan 7, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · $2.9M · 75,000 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Anders JackChief Financial OfficerExercise or conversion · $425K · 10,000 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Horn Margaret AChief Operating OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 75,000 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Anders JackChief Financial OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 16 filings
| Filed | What it is |
|---|---|
| Oct 13, 20268-K | New financial obligation; Other events |
| Sep 1, 20268-K | Material definitive agreement; New financial obligation |
| Aug 26, 20268-K | Other events |
| Aug 5, 202610-Q | Quarterly report, Q2 2026 — net income −$644.4M, EPS −$3.06 |
| Aug 5, 20268-K | Earnings release — EPS −$2.34 vs −$1.93 est. (−21.2%) 0.3% |
| Jun 22, 20268-K | Directors or officers; compensation; Shareholder vote results |
| May 6, 202610-Q | Quarterly report, Q1 2026 — net income −$453.8M, EPS −$2.29 |
| May 6, 20268-K | Earnings release — EPS −$2.29 vs −$1.83 est. (−25.1%) 5.7% |
| Apr 28, 2026DEFA14A | Additional proxy materials |
| Apr 28, 2026ARS | Annual report to shareholders |
| Apr 27, 2026DEF 14A | Proxy statement |
| Apr 17, 20268-K | Material definitive agreement; New financial obligation; Other events |
| Apr 16, 20268-K | Other events |
| Apr 13, 20268-K | Other events |
| Feb 25, 202610-K | Annual report, FY2025 — revenue $0, net income −$1.13B, EPS −$5.95 |
| Feb 25, 20268-K | Earnings release — EPS −$1.86 vs −$1.56 est. (−19.2%); revenue $0 1.1% |
2025 · 16 filings
| Filed | What it is |
|---|---|
| Nov 5, 202510-Q | Quarterly report, Q3 2025 — net income −$305.2M, EPS −$1.61 |
| Nov 5, 20258-K | Earnings release — EPS −$1.61 vs −$1.39 est. (−15.8%) 3.4% |
| Oct 17, 20258-K | Other events |
| Sep 10, 20258-K | Other events |
| Aug 6, 202510-Q | Quarterly report, Q2 2025 — net income −$247.8M, EPS −$1.31 |
| Aug 6, 20258-K | Earnings release — EPS −$1.31 vs −$0.94 est. (−39.4%) 4.7% |
| Jun 27, 20258-K | Shareholder vote results |
| Jun 24, 20258-K | Material definitive agreement; New financial obligation; Regulation FD disclosure |
| Jun 18, 20258-K | Directors or officers; compensation |
| May 7, 202510-Q | Quarterly report, Q1 2025 — net income −$213.4M, EPS −$1.13 |
| May 7, 20258-K | Earnings release — EPS −$1.13 vs −$1.12 est. (−0.9%) 11.3% |
| Apr 29, 2025ARS | Annual report to shareholders |
| Apr 29, 2025DEFA14A | Additional proxy materials |
| Apr 29, 2025DEF 14A | Proxy statement |
| Feb 26, 202510-K | Annual report, FY2024 — revenue $0 (−100% y/y), net income −$600.1M, EPS −$3.58 |
| Feb 26, 20258-K | Earnings release — EPS −$1.12 vs −$0.99 est. (−13.1%); revenue $0 (−100% y/y) 3.5% |
2024 · 18 filings
| Filed | What it is |
|---|---|
| Dec 5, 20248-K | Other events |
| Dec 2, 20248-K | Other events |
| Nov 6, 202410-Q | Quarterly report, Q3 2024 — revenue $0, net income −$156.3M, EPS −$0.94 |
| Nov 6, 20248-K | Earnings release — EPS −$0.94 vs −$0.89 est. (−5.6%); revenue $0 0.5% |
| Oct 25, 20248-K | Other events |
| Oct 23, 20248-K | Other events |
| Aug 7, 202410-Q | Quarterly report, Q2 2024 — revenue $0, net income −$133.2M, EPS −$0.81 |
| Aug 7, 20248-K | Earnings release — EPS −$0.81 vs −$0.77 est. (−5.2%); revenue $0 0.7% |
| Jul 15, 20248-K | Regulation FD disclosure; Other events |
| Jun 24, 20248-K | Shareholder vote results |
| May 8, 202410-Q | Quarterly report, Q1 2024 — revenue $0 (−100% y/y), net income −$116.0M, EPS −$0.70 |
| May 8, 20248-K | Earnings release — EPS −$0.70 vs −$0.75 est. (+6.7%); revenue $0 (−100% y/y) 2.2% |
| Apr 25, 2024ARS | Annual report to shareholders |
| Apr 25, 2024DEFA14A | Additional proxy materials |
| Apr 25, 2024DEF 14A | Proxy statement |
| Feb 26, 202410-K | Annual report, FY2023 — revenue $11.6M (−67% y/y), net income −$436.4M, EPS −$3.86 |
| Feb 26, 20248-K | Earnings release — EPS −$1.14 vs −$0.86 est. (−32.6%); revenue $742K (−95% y/y) 0.8% |
| Jan 9, 20248-K | Results of operations; Regulation FD disclosure |
2023 · 23 filings — 13 × 8-K, 3 × 10-Q, 2 × DEFA14A and 5 other forms
| Filed | What it is |
|---|---|
| Nov 6, 202310-Q | Quarterly report, Q3 2023 — revenue $0 (−100% y/y), net income −$108.4M |
| Nov 1, 2023DEFA14A | Additional proxy materials |
| Sep 29, 2023DEFM14A | Merger proxy statement |
| Aug 8, 202310-Q | Quarterly report |
| May 8, 202310-Q | Quarterly report, Q1 2023 — revenue $7.0M (−7% y/y), net income −$68.1M, EPS −$0.72 |
| Apr 26, 2023ARS | Annual report to shareholders |
| Apr 26, 2023DEFA14A | Additional proxy materials |
| Apr 26, 2023DEF 14A | Proxy statement |
| Feb 27, 202310-K | Annual report, FY2022 — revenue $35.4M (+20% y/y), net income −$248.7M, EPS −$3.08 |
14 current reports (8-K) not listed; the year is on EDGAR.
2022 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202210-Q | Quarterly report, Q3 2022 — revenue $3.4M (+205% y/y), net income −$73.3M, EPS −$0.87 |
| Aug 9, 202210-Q | Quarterly report, Q2 2022 — revenue $9.1M (+5% y/y), net income −$61.2M, EPS −$0.82 |
| May 9, 202210-Q | Quarterly report, Q1 2022 — revenue $7.6M (−25% y/y), net income −$57.6M, EPS −$0.78 |
| Apr 26, 2022DEFA14A | Additional proxy materials |
| Apr 26, 2022DEF 14A | Proxy statement |
| Feb 28, 202210-K | Annual report, FY2021 — revenue $29.4M (−32% y/y), net income −$187.1M, EPS −$2.57 |
11 current reports (8-K) not listed; the year is on EDGAR.
2021 · 16 filings — 9 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 10, 202110-Q | Quarterly report, Q3 2021 — revenue $1.1M (−91% y/y), net income −$52.9M, EPS −$0.72 |
| Aug 11, 202110-Q | Quarterly report, Q2 2021 — revenue $8.7M (−13% y/y), net income −$44.3M, EPS −$0.60 |
| May 10, 202110-Q | Quarterly report, Q1 2021 — revenue $10.1M (−12% y/y), net income −$37.2M |
| May 3, 2021DEFA14A | Additional proxy materials |
| Apr 28, 2021DEFA14A | Additional proxy materials |
| Apr 28, 2021DEF 14A | Proxy statement |
| Mar 2, 202110-K | Annual report, FY2020 — revenue $43.0M (−14% y/y), net income −$108.2M, EPS −$2.01 |
9 current reports (8-K) not listed; the year is on EDGAR.
2020 · 12 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K
| Filed | What it is |
|---|---|
| Nov 12, 202010-Q | Quarterly report, Q3 2020 — revenue $12.7M (+1% y/y), net income −$27.2M |
| Aug 10, 202010-Q | Quarterly report, Q2 2020 — revenue $10.0M (−18% y/y), net income −$27.2M |
| May 14, 202010-Q | Quarterly report, Q1 2020 — revenue $11.5M (−12% y/y), net income −$19.5M |
| Mar 30, 202010-K | Annual report |
8 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 123 filings — 57 × 4, 47 × 144, 6 × SCHEDULE 13G/A and 6 other forms
| Filed | What it is |
|---|---|
| Oct 1, 20264 | Insider transaction (Form 4) |
| Sep 29, 20264 | Insider transaction (Form 4) |
| Sep 29, 2026144 | Notice of proposed sale (Form 144) |
| Sep 28, 20264 | Insider transaction (Form 4) |
| Sep 25, 2026144 | Notice of proposed sale (Form 144) |
| Sep 24, 20264 | Insider transaction (Form 4) |
| Sep 24, 2026144 | Notice of proposed sale (Form 144) |
| Sep 22, 20264 | Insider transaction (Form 4) |
| Sep 22, 2026144 | Notice of proposed sale (Form 144) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 20264 | Insider transaction (Form 4) |
The newest 25 of 123 shown; the full year is on EDGAR.
2025 · 107 filings — 54 × 4, 40 × 144, 7 × SCHEDULE 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 12, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 20, 20254 | Insider transaction (Form 4) |
| Nov 20, 20254 | Insider transaction (Form 4) |
| Nov 18, 2025144 | Notice of proposed sale (Form 144) |
| Nov 18, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 12, 20254 | Insider transaction (Form 4) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 107 shown; the full year is on EDGAR.
2024 · 156 filings — 69 × 4, 59 × 144, 9 × SC 13G/A and 8 other forms
| Filed | What it is |
|---|---|
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 9, 20244 | Insider transaction (Form 4) |
| Dec 5, 2024424B5 | Prospectus supplement |
| Dec 4, 2024FWP | Free writing prospectus |
| Dec 2, 2024424B5 | Prospectus supplement |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 15, 2024144 | Notice of proposed sale (Form 144) |
| Nov 15, 20244 | Insider transaction (Form 4) |
| Nov 13, 2024144 | Notice of proposed sale (Form 144) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 8, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 6, 2024144 | Notice of proposed sale (Form 144) |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Nov 4, 20244 | Insider transaction (Form 4) |
| Nov 1, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 156 shown; the full year is on EDGAR.
2023 · 115 filings — 51 × 4, 30 × 144, 9 × 425 and 14 other forms
Counted, not listed; the year is on EDGAR.
2022 · 64 filings — 46 × 4, 9 × SC 13G/A, 3 × SC 13G and 4 other forms
Counted, not listed; the year is on EDGAR.
2021 · 70 filings — 45 × 4, 7 × SC 13G, 3 × SC 13G/A and 13 other forms
Counted, not listed; the year is on EDGAR.
2020 · 95 filings — 50 × 4, 16 × 3, 7 × CORRESP and 13 other forms
Counted, not listed; the year is on EDGAR.
2019 · 8 filings — 2 × SEC STAFF LETTER, 2 × UPLOAD, 1 × D and 3 other forms
Counted, not listed; the year is on EDGAR.
2018 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
2016 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
About this data#
Revolution Medicines Inc. (RVMD) has 858 filings on EDGAR going back to 2016: 7 annual reports, 20 quarterly reports and 72 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 25, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 13, 2026, covered new financial obligation; other events. Over the last 13 months insiders sold $140.5M in 46 sales and bought nothing on the open market; 69 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Revolution Medicines Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read RVMD's latest 10-K?
- RVMD's latest annual report, a 10-K, was filed on Feb 25, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did RVMD last file an 8-K?
- On Oct 13, 2026 it covered new financial obligation; other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 5, 2026.
- Are RVMD insiders buying or selling?
- Over the last 13 months insiders sold $140.5M in 46 sales and bought nothing on the open market; 69 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Sandler Alan B. (Chief Development Officer) sold 6,309 shares on Sep 29, 2026 for $1.3M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has RVMD made?
- 858 filings are on EDGAR under the registrant records that have been Revolution Medicines Inc., going back to 2016; 585 of them are insider ownership forms (Forms 3, 4, 5 and 144).